The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.
Thomas M. O'Dorisio
No relevant relationships to disclose
Alexandria T. Phan
No relevant relationships to disclose
Robert M. Langdon
No relevant relationships to disclose
Billie J. Marek
No relevant relationships to disclose
Nadeem Ikhlaque
No relevant relationships to disclose
Emily K. Bergsland
Consultant or Advisory Role - Novartis (U); Pfizer (U)
Joel Freiman
Employment or Leadership Position - Lexicon
Linda Law
Employment or Leadership Position - Lexicon
Phillip Lee Banks
Employment or Leadership Position - Lexicon
Kenneth Frazier
Employment or Leadership Position - Lexicon
Stock Ownership - Lexicon
Jessica Jackson
Employment or Leadership Position - Lexicon
Brian Zambrowicz
Employment or Leadership Position - Lexicon
Stock Ownership - Lexicon
Matthew Kulke
Consultant or Advisory Role - Lexicon